Recent

% | $
Quotes you view appear here for quick access.

Anacor Pharmaceuticals, Inc. (ANAC) Message Board

  • sandra3953 sandra3953 Jan 24, 2012 1:53 PM Flag

    Potentially a huge, unserved market

    MD Perspective : Onchomycosis ( nail bed fungal infection) is a VERY common, difficult to treat condition . Essentially, current topical medications are marginally effective. Nail removal not an alternative easy to contemplate, and again in some patients ineffective. The current systemic medication poses a definite serious health risk in some patients ie- Liver failure and a serious Immune type ailment. If Anacor's current phase three clinical investigation proves successful , their medication will be accepted as the standard of care for most Dermatologists and Podiatrists , as well as other MDs. The firms other drug candidates also seem attractive treatments for atopic dermatitis and psoriasis , again, two common conditions where newer alternatives to current therapy needed.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ANAC
99.200.00(0.00%)Jun 23 4:00 PMEDT